Central precocious puberty: revisiting the diagnosis and therapeutic management
ABSTRACT Clinical and laboratory diagnosis and treatment of central precocious puberty (CPP) remain challenging due to lack of standardization. The aim of this revision was to address the diagnostic and therapeutic features of CPP in Brazil based on relevant international literature and availability...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Vinícius Nahime Brito [verfasserIn] Angela Maria Spinola-Castro [verfasserIn] Cristiane Kochi [verfasserIn] Cristiane Kopacek [verfasserIn] Paulo César Alves da Silva [verfasserIn] Gil Guerra-Júnior [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Schlagwörter: |
|---|
| Übergeordnetes Werk: |
In: Archives of Endocrinology and Metabolism - Brazilian Society of Endocrinology and Metabolism, 2017 |
|---|
| Links: |
|---|
| DOI / URN: |
10.1590/2359-3997000000144 |
|---|
| Katalog-ID: |
DOAJ056983166 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ056983166 | ||
| 003 | DE-627 | ||
| 005 | 20230308205216.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230227nuuuuuuuuxx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1590/2359-3997000000144 |2 doi | |
| 035 | |a (DE-627)DOAJ056983166 | ||
| 035 | |a (DE-599)DOAJa389ff385f434983afbf79f948d87294 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 050 | 0 | |a RC648-665 | |
| 100 | 0 | |a Vinícius Nahime Brito |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Central precocious puberty: revisiting the diagnosis and therapeutic management |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a ABSTRACT Clinical and laboratory diagnosis and treatment of central precocious puberty (CPP) remain challenging due to lack of standardization. The aim of this revision was to address the diagnostic and therapeutic features of CPP in Brazil based on relevant international literature and availability of the existing therapies in the country. The diagnosis of CPP is based mainly on clinical and biochemical parameters, and a period of follow-up is desirable to define the “progressive” form of sexual precocity. This occurs due to the broad spectrum of pubertal development, including isolated premature thelarche, constitutional growth and puberty acceleration, progressive and nonprogressive CPP, and early puberty. Measurement of basal and stimulated LH levels remains challenging, considering that the levels are not always in the pubertal range at baseline, short-acting GnRH is not readily available in Brazil, and the cutoff values differ according to the laboratory assay. When CPP is suspected but basal LH values are at prepubertal range, a stimulation test with short-acting or long-acting monthly GnRH is a diagnostic option. In Brazil, the treatment of choice for progressive CPP and early puberty is a long-acting GnRH analog (GnRHa) administered once a month or every 3 months. In Brazil, formulations of GnRHa (leuprorelin and triptorelin) are available and commonly administered, including 1-month depot leuprorelin 3.75 mg and 7.5 mg, 1-month depot triptorelin 3.75 mg, and 3-month depot leuprorelin 11.25 mg. Monthly or 3-month depot GnRHa are effective and safe to treat CPP. Arch Endocrinol Metab. 2016;60(2):163-72 | ||
| 650 | 4 | |a Precocious puberty | |
| 650 | 4 | |a sexual maturation | |
| 650 | 4 | |a gonadotropin-realising hormone | |
| 650 | 4 | |a luteinizing hormone | |
| 650 | 4 | |a long-acting GnRH analog | |
| 653 | 0 | |a Medicine | |
| 653 | 0 | |a R | |
| 653 | 0 | |a Diseases of the endocrine glands. Clinical endocrinology | |
| 700 | 0 | |a Angela Maria Spinola-Castro |e verfasserin |4 aut | |
| 700 | 0 | |a Cristiane Kochi |e verfasserin |4 aut | |
| 700 | 0 | |a Cristiane Kopacek |e verfasserin |4 aut | |
| 700 | 0 | |a Paulo César Alves da Silva |e verfasserin |4 aut | |
| 700 | 0 | |a Gil Guerra-Júnior |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Archives of Endocrinology and Metabolism |d Brazilian Society of Endocrinology and Metabolism, 2017 |w (DE-627)1760589977 |x 23594292 |7 nnns |
| 856 | 4 | 0 | |u https://doi.org/10.1590/2359-3997000000144 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/a389ff385f434983afbf79f948d87294 |z kostenfrei |
| 856 | 4 | 0 | |u http://www.scielo.br/scielo.php?script=sci_arttext&pid=S2359-39972016000200163&lng=en&tlng=en |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2359-4292 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| author_variant |
v n b vnb a m s c amsc c k ck c k ck p c a d s pcads g g j ggj |
|---|---|
| matchkey_str |
article:23594292:uuuuuuuu::etapeoiupbryeiiighdanssnt |
| callnumber-subject-code |
RC |
| allfields |
10.1590/2359-3997000000144 doi (DE-627)DOAJ056983166 (DE-599)DOAJa389ff385f434983afbf79f948d87294 DE-627 ger DE-627 rakwb eng RC648-665 Vinícius Nahime Brito verfasserin aut Central precocious puberty: revisiting the diagnosis and therapeutic management Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier ABSTRACT Clinical and laboratory diagnosis and treatment of central precocious puberty (CPP) remain challenging due to lack of standardization. The aim of this revision was to address the diagnostic and therapeutic features of CPP in Brazil based on relevant international literature and availability of the existing therapies in the country. The diagnosis of CPP is based mainly on clinical and biochemical parameters, and a period of follow-up is desirable to define the “progressive” form of sexual precocity. This occurs due to the broad spectrum of pubertal development, including isolated premature thelarche, constitutional growth and puberty acceleration, progressive and nonprogressive CPP, and early puberty. Measurement of basal and stimulated LH levels remains challenging, considering that the levels are not always in the pubertal range at baseline, short-acting GnRH is not readily available in Brazil, and the cutoff values differ according to the laboratory assay. When CPP is suspected but basal LH values are at prepubertal range, a stimulation test with short-acting or long-acting monthly GnRH is a diagnostic option. In Brazil, the treatment of choice for progressive CPP and early puberty is a long-acting GnRH analog (GnRHa) administered once a month or every 3 months. In Brazil, formulations of GnRHa (leuprorelin and triptorelin) are available and commonly administered, including 1-month depot leuprorelin 3.75 mg and 7.5 mg, 1-month depot triptorelin 3.75 mg, and 3-month depot leuprorelin 11.25 mg. Monthly or 3-month depot GnRHa are effective and safe to treat CPP. Arch Endocrinol Metab. 2016;60(2):163-72 Precocious puberty sexual maturation gonadotropin-realising hormone luteinizing hormone long-acting GnRH analog Medicine R Diseases of the endocrine glands. Clinical endocrinology Angela Maria Spinola-Castro verfasserin aut Cristiane Kochi verfasserin aut Cristiane Kopacek verfasserin aut Paulo César Alves da Silva verfasserin aut Gil Guerra-Júnior verfasserin aut In Archives of Endocrinology and Metabolism Brazilian Society of Endocrinology and Metabolism, 2017 (DE-627)1760589977 23594292 nnns https://doi.org/10.1590/2359-3997000000144 kostenfrei https://doaj.org/article/a389ff385f434983afbf79f948d87294 kostenfrei http://www.scielo.br/scielo.php?script=sci_arttext&pid=S2359-39972016000200163&lng=en&tlng=en kostenfrei https://doaj.org/toc/2359-4292 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR |
| spelling |
10.1590/2359-3997000000144 doi (DE-627)DOAJ056983166 (DE-599)DOAJa389ff385f434983afbf79f948d87294 DE-627 ger DE-627 rakwb eng RC648-665 Vinícius Nahime Brito verfasserin aut Central precocious puberty: revisiting the diagnosis and therapeutic management Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier ABSTRACT Clinical and laboratory diagnosis and treatment of central precocious puberty (CPP) remain challenging due to lack of standardization. The aim of this revision was to address the diagnostic and therapeutic features of CPP in Brazil based on relevant international literature and availability of the existing therapies in the country. The diagnosis of CPP is based mainly on clinical and biochemical parameters, and a period of follow-up is desirable to define the “progressive” form of sexual precocity. This occurs due to the broad spectrum of pubertal development, including isolated premature thelarche, constitutional growth and puberty acceleration, progressive and nonprogressive CPP, and early puberty. Measurement of basal and stimulated LH levels remains challenging, considering that the levels are not always in the pubertal range at baseline, short-acting GnRH is not readily available in Brazil, and the cutoff values differ according to the laboratory assay. When CPP is suspected but basal LH values are at prepubertal range, a stimulation test with short-acting or long-acting monthly GnRH is a diagnostic option. In Brazil, the treatment of choice for progressive CPP and early puberty is a long-acting GnRH analog (GnRHa) administered once a month or every 3 months. In Brazil, formulations of GnRHa (leuprorelin and triptorelin) are available and commonly administered, including 1-month depot leuprorelin 3.75 mg and 7.5 mg, 1-month depot triptorelin 3.75 mg, and 3-month depot leuprorelin 11.25 mg. Monthly or 3-month depot GnRHa are effective and safe to treat CPP. Arch Endocrinol Metab. 2016;60(2):163-72 Precocious puberty sexual maturation gonadotropin-realising hormone luteinizing hormone long-acting GnRH analog Medicine R Diseases of the endocrine glands. Clinical endocrinology Angela Maria Spinola-Castro verfasserin aut Cristiane Kochi verfasserin aut Cristiane Kopacek verfasserin aut Paulo César Alves da Silva verfasserin aut Gil Guerra-Júnior verfasserin aut In Archives of Endocrinology and Metabolism Brazilian Society of Endocrinology and Metabolism, 2017 (DE-627)1760589977 23594292 nnns https://doi.org/10.1590/2359-3997000000144 kostenfrei https://doaj.org/article/a389ff385f434983afbf79f948d87294 kostenfrei http://www.scielo.br/scielo.php?script=sci_arttext&pid=S2359-39972016000200163&lng=en&tlng=en kostenfrei https://doaj.org/toc/2359-4292 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR |
| allfields_unstemmed |
10.1590/2359-3997000000144 doi (DE-627)DOAJ056983166 (DE-599)DOAJa389ff385f434983afbf79f948d87294 DE-627 ger DE-627 rakwb eng RC648-665 Vinícius Nahime Brito verfasserin aut Central precocious puberty: revisiting the diagnosis and therapeutic management Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier ABSTRACT Clinical and laboratory diagnosis and treatment of central precocious puberty (CPP) remain challenging due to lack of standardization. The aim of this revision was to address the diagnostic and therapeutic features of CPP in Brazil based on relevant international literature and availability of the existing therapies in the country. The diagnosis of CPP is based mainly on clinical and biochemical parameters, and a period of follow-up is desirable to define the “progressive” form of sexual precocity. This occurs due to the broad spectrum of pubertal development, including isolated premature thelarche, constitutional growth and puberty acceleration, progressive and nonprogressive CPP, and early puberty. Measurement of basal and stimulated LH levels remains challenging, considering that the levels are not always in the pubertal range at baseline, short-acting GnRH is not readily available in Brazil, and the cutoff values differ according to the laboratory assay. When CPP is suspected but basal LH values are at prepubertal range, a stimulation test with short-acting or long-acting monthly GnRH is a diagnostic option. In Brazil, the treatment of choice for progressive CPP and early puberty is a long-acting GnRH analog (GnRHa) administered once a month or every 3 months. In Brazil, formulations of GnRHa (leuprorelin and triptorelin) are available and commonly administered, including 1-month depot leuprorelin 3.75 mg and 7.5 mg, 1-month depot triptorelin 3.75 mg, and 3-month depot leuprorelin 11.25 mg. Monthly or 3-month depot GnRHa are effective and safe to treat CPP. Arch Endocrinol Metab. 2016;60(2):163-72 Precocious puberty sexual maturation gonadotropin-realising hormone luteinizing hormone long-acting GnRH analog Medicine R Diseases of the endocrine glands. Clinical endocrinology Angela Maria Spinola-Castro verfasserin aut Cristiane Kochi verfasserin aut Cristiane Kopacek verfasserin aut Paulo César Alves da Silva verfasserin aut Gil Guerra-Júnior verfasserin aut In Archives of Endocrinology and Metabolism Brazilian Society of Endocrinology and Metabolism, 2017 (DE-627)1760589977 23594292 nnns https://doi.org/10.1590/2359-3997000000144 kostenfrei https://doaj.org/article/a389ff385f434983afbf79f948d87294 kostenfrei http://www.scielo.br/scielo.php?script=sci_arttext&pid=S2359-39972016000200163&lng=en&tlng=en kostenfrei https://doaj.org/toc/2359-4292 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR |
| allfieldsGer |
10.1590/2359-3997000000144 doi (DE-627)DOAJ056983166 (DE-599)DOAJa389ff385f434983afbf79f948d87294 DE-627 ger DE-627 rakwb eng RC648-665 Vinícius Nahime Brito verfasserin aut Central precocious puberty: revisiting the diagnosis and therapeutic management Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier ABSTRACT Clinical and laboratory diagnosis and treatment of central precocious puberty (CPP) remain challenging due to lack of standardization. The aim of this revision was to address the diagnostic and therapeutic features of CPP in Brazil based on relevant international literature and availability of the existing therapies in the country. The diagnosis of CPP is based mainly on clinical and biochemical parameters, and a period of follow-up is desirable to define the “progressive” form of sexual precocity. This occurs due to the broad spectrum of pubertal development, including isolated premature thelarche, constitutional growth and puberty acceleration, progressive and nonprogressive CPP, and early puberty. Measurement of basal and stimulated LH levels remains challenging, considering that the levels are not always in the pubertal range at baseline, short-acting GnRH is not readily available in Brazil, and the cutoff values differ according to the laboratory assay. When CPP is suspected but basal LH values are at prepubertal range, a stimulation test with short-acting or long-acting monthly GnRH is a diagnostic option. In Brazil, the treatment of choice for progressive CPP and early puberty is a long-acting GnRH analog (GnRHa) administered once a month or every 3 months. In Brazil, formulations of GnRHa (leuprorelin and triptorelin) are available and commonly administered, including 1-month depot leuprorelin 3.75 mg and 7.5 mg, 1-month depot triptorelin 3.75 mg, and 3-month depot leuprorelin 11.25 mg. Monthly or 3-month depot GnRHa are effective and safe to treat CPP. Arch Endocrinol Metab. 2016;60(2):163-72 Precocious puberty sexual maturation gonadotropin-realising hormone luteinizing hormone long-acting GnRH analog Medicine R Diseases of the endocrine glands. Clinical endocrinology Angela Maria Spinola-Castro verfasserin aut Cristiane Kochi verfasserin aut Cristiane Kopacek verfasserin aut Paulo César Alves da Silva verfasserin aut Gil Guerra-Júnior verfasserin aut In Archives of Endocrinology and Metabolism Brazilian Society of Endocrinology and Metabolism, 2017 (DE-627)1760589977 23594292 nnns https://doi.org/10.1590/2359-3997000000144 kostenfrei https://doaj.org/article/a389ff385f434983afbf79f948d87294 kostenfrei http://www.scielo.br/scielo.php?script=sci_arttext&pid=S2359-39972016000200163&lng=en&tlng=en kostenfrei https://doaj.org/toc/2359-4292 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR |
| allfieldsSound |
10.1590/2359-3997000000144 doi (DE-627)DOAJ056983166 (DE-599)DOAJa389ff385f434983afbf79f948d87294 DE-627 ger DE-627 rakwb eng RC648-665 Vinícius Nahime Brito verfasserin aut Central precocious puberty: revisiting the diagnosis and therapeutic management Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier ABSTRACT Clinical and laboratory diagnosis and treatment of central precocious puberty (CPP) remain challenging due to lack of standardization. The aim of this revision was to address the diagnostic and therapeutic features of CPP in Brazil based on relevant international literature and availability of the existing therapies in the country. The diagnosis of CPP is based mainly on clinical and biochemical parameters, and a period of follow-up is desirable to define the “progressive” form of sexual precocity. This occurs due to the broad spectrum of pubertal development, including isolated premature thelarche, constitutional growth and puberty acceleration, progressive and nonprogressive CPP, and early puberty. Measurement of basal and stimulated LH levels remains challenging, considering that the levels are not always in the pubertal range at baseline, short-acting GnRH is not readily available in Brazil, and the cutoff values differ according to the laboratory assay. When CPP is suspected but basal LH values are at prepubertal range, a stimulation test with short-acting or long-acting monthly GnRH is a diagnostic option. In Brazil, the treatment of choice for progressive CPP and early puberty is a long-acting GnRH analog (GnRHa) administered once a month or every 3 months. In Brazil, formulations of GnRHa (leuprorelin and triptorelin) are available and commonly administered, including 1-month depot leuprorelin 3.75 mg and 7.5 mg, 1-month depot triptorelin 3.75 mg, and 3-month depot leuprorelin 11.25 mg. Monthly or 3-month depot GnRHa are effective and safe to treat CPP. Arch Endocrinol Metab. 2016;60(2):163-72 Precocious puberty sexual maturation gonadotropin-realising hormone luteinizing hormone long-acting GnRH analog Medicine R Diseases of the endocrine glands. Clinical endocrinology Angela Maria Spinola-Castro verfasserin aut Cristiane Kochi verfasserin aut Cristiane Kopacek verfasserin aut Paulo César Alves da Silva verfasserin aut Gil Guerra-Júnior verfasserin aut In Archives of Endocrinology and Metabolism Brazilian Society of Endocrinology and Metabolism, 2017 (DE-627)1760589977 23594292 nnns https://doi.org/10.1590/2359-3997000000144 kostenfrei https://doaj.org/article/a389ff385f434983afbf79f948d87294 kostenfrei http://www.scielo.br/scielo.php?script=sci_arttext&pid=S2359-39972016000200163&lng=en&tlng=en kostenfrei https://doaj.org/toc/2359-4292 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR |
| language |
English |
| source |
In Archives of Endocrinology and Metabolism |
| sourceStr |
In Archives of Endocrinology and Metabolism |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
Precocious puberty sexual maturation gonadotropin-realising hormone luteinizing hormone long-acting GnRH analog Medicine R Diseases of the endocrine glands. Clinical endocrinology |
| isfreeaccess_bool |
true |
| container_title |
Archives of Endocrinology and Metabolism |
| authorswithroles_txt_mv |
Vinícius Nahime Brito @@aut@@ Angela Maria Spinola-Castro @@aut@@ Cristiane Kochi @@aut@@ Cristiane Kopacek @@aut@@ Paulo César Alves da Silva @@aut@@ Gil Guerra-Júnior @@aut@@ |
| publishDateDaySort_date |
2024-01-01T00:00:00Z |
| hierarchy_top_id |
1760589977 |
| id |
DOAJ056983166 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ056983166</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230308205216.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230227nuuuuuuuuxx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1590/2359-3997000000144</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ056983166</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJa389ff385f434983afbf79f948d87294</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC648-665</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Vinícius Nahime Brito</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Central precocious puberty: revisiting the diagnosis and therapeutic management</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">ABSTRACT Clinical and laboratory diagnosis and treatment of central precocious puberty (CPP) remain challenging due to lack of standardization. The aim of this revision was to address the diagnostic and therapeutic features of CPP in Brazil based on relevant international literature and availability of the existing therapies in the country. The diagnosis of CPP is based mainly on clinical and biochemical parameters, and a period of follow-up is desirable to define the “progressive” form of sexual precocity. This occurs due to the broad spectrum of pubertal development, including isolated premature thelarche, constitutional growth and puberty acceleration, progressive and nonprogressive CPP, and early puberty. Measurement of basal and stimulated LH levels remains challenging, considering that the levels are not always in the pubertal range at baseline, short-acting GnRH is not readily available in Brazil, and the cutoff values differ according to the laboratory assay. When CPP is suspected but basal LH values are at prepubertal range, a stimulation test with short-acting or long-acting monthly GnRH is a diagnostic option. In Brazil, the treatment of choice for progressive CPP and early puberty is a long-acting GnRH analog (GnRHa) administered once a month or every 3 months. In Brazil, formulations of GnRHa (leuprorelin and triptorelin) are available and commonly administered, including 1-month depot leuprorelin 3.75 mg and 7.5 mg, 1-month depot triptorelin 3.75 mg, and 3-month depot leuprorelin 11.25 mg. Monthly or 3-month depot GnRHa are effective and safe to treat CPP. Arch Endocrinol Metab. 2016;60(2):163-72</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Precocious puberty</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">sexual maturation</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">gonadotropin-realising hormone</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">luteinizing hormone</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">long-acting GnRH analog</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medicine</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">R</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Diseases of the endocrine glands. Clinical endocrinology</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Angela Maria Spinola-Castro</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Cristiane Kochi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Cristiane Kopacek</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Paulo César Alves da Silva</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Gil Guerra-Júnior</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Archives of Endocrinology and Metabolism</subfield><subfield code="d">Brazilian Society of Endocrinology and Metabolism, 2017</subfield><subfield code="w">(DE-627)1760589977</subfield><subfield code="x">23594292</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1590/2359-3997000000144</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/a389ff385f434983afbf79f948d87294</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://www.scielo.br/scielo.php?script=sci_arttext&pid=S2359-39972016000200163&lng=en&tlng=en</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2359-4292</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield></record></collection>
|
| callnumber-first |
R - Medicine |
| author |
Vinícius Nahime Brito |
| spellingShingle |
Vinícius Nahime Brito misc RC648-665 misc Precocious puberty misc sexual maturation misc gonadotropin-realising hormone misc luteinizing hormone misc long-acting GnRH analog misc Medicine misc R misc Diseases of the endocrine glands. Clinical endocrinology Central precocious puberty: revisiting the diagnosis and therapeutic management |
| authorStr |
Vinícius Nahime Brito |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)1760589977 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut aut aut aut aut aut |
| collection |
DOAJ |
| remote_str |
true |
| callnumber-label |
RC648-665 |
| illustrated |
Not Illustrated |
| issn |
23594292 |
| topic_title |
RC648-665 Central precocious puberty: revisiting the diagnosis and therapeutic management Precocious puberty sexual maturation gonadotropin-realising hormone luteinizing hormone long-acting GnRH analog |
| topic |
misc RC648-665 misc Precocious puberty misc sexual maturation misc gonadotropin-realising hormone misc luteinizing hormone misc long-acting GnRH analog misc Medicine misc R misc Diseases of the endocrine glands. Clinical endocrinology |
| topic_unstemmed |
misc RC648-665 misc Precocious puberty misc sexual maturation misc gonadotropin-realising hormone misc luteinizing hormone misc long-acting GnRH analog misc Medicine misc R misc Diseases of the endocrine glands. Clinical endocrinology |
| topic_browse |
misc RC648-665 misc Precocious puberty misc sexual maturation misc gonadotropin-realising hormone misc luteinizing hormone misc long-acting GnRH analog misc Medicine misc R misc Diseases of the endocrine glands. Clinical endocrinology |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
Archives of Endocrinology and Metabolism |
| hierarchy_parent_id |
1760589977 |
| hierarchy_top_title |
Archives of Endocrinology and Metabolism |
| isfreeaccess_txt |
true |
| familylinks_str_mv |
(DE-627)1760589977 |
| title |
Central precocious puberty: revisiting the diagnosis and therapeutic management |
| ctrlnum |
(DE-627)DOAJ056983166 (DE-599)DOAJa389ff385f434983afbf79f948d87294 |
| title_full |
Central precocious puberty: revisiting the diagnosis and therapeutic management |
| author_sort |
Vinícius Nahime Brito |
| journal |
Archives of Endocrinology and Metabolism |
| journalStr |
Archives of Endocrinology and Metabolism |
| callnumber-first-code |
R |
| lang_code |
eng |
| isOA_bool |
true |
| recordtype |
marc |
| contenttype_str_mv |
txt |
| author_browse |
Vinícius Nahime Brito Angela Maria Spinola-Castro Cristiane Kochi Cristiane Kopacek Paulo César Alves da Silva Gil Guerra-Júnior |
| class |
RC648-665 |
| format_se |
Elektronische Aufsätze |
| author-letter |
Vinícius Nahime Brito |
| doi_str_mv |
10.1590/2359-3997000000144 |
| author2-role |
verfasserin |
| title_sort |
central precocious puberty: revisiting the diagnosis and therapeutic management |
| callnumber |
RC648-665 |
| title_auth |
Central precocious puberty: revisiting the diagnosis and therapeutic management |
| abstract |
ABSTRACT Clinical and laboratory diagnosis and treatment of central precocious puberty (CPP) remain challenging due to lack of standardization. The aim of this revision was to address the diagnostic and therapeutic features of CPP in Brazil based on relevant international literature and availability of the existing therapies in the country. The diagnosis of CPP is based mainly on clinical and biochemical parameters, and a period of follow-up is desirable to define the “progressive” form of sexual precocity. This occurs due to the broad spectrum of pubertal development, including isolated premature thelarche, constitutional growth and puberty acceleration, progressive and nonprogressive CPP, and early puberty. Measurement of basal and stimulated LH levels remains challenging, considering that the levels are not always in the pubertal range at baseline, short-acting GnRH is not readily available in Brazil, and the cutoff values differ according to the laboratory assay. When CPP is suspected but basal LH values are at prepubertal range, a stimulation test with short-acting or long-acting monthly GnRH is a diagnostic option. In Brazil, the treatment of choice for progressive CPP and early puberty is a long-acting GnRH analog (GnRHa) administered once a month or every 3 months. In Brazil, formulations of GnRHa (leuprorelin and triptorelin) are available and commonly administered, including 1-month depot leuprorelin 3.75 mg and 7.5 mg, 1-month depot triptorelin 3.75 mg, and 3-month depot leuprorelin 11.25 mg. Monthly or 3-month depot GnRHa are effective and safe to treat CPP. Arch Endocrinol Metab. 2016;60(2):163-72 |
| abstractGer |
ABSTRACT Clinical and laboratory diagnosis and treatment of central precocious puberty (CPP) remain challenging due to lack of standardization. The aim of this revision was to address the diagnostic and therapeutic features of CPP in Brazil based on relevant international literature and availability of the existing therapies in the country. The diagnosis of CPP is based mainly on clinical and biochemical parameters, and a period of follow-up is desirable to define the “progressive” form of sexual precocity. This occurs due to the broad spectrum of pubertal development, including isolated premature thelarche, constitutional growth and puberty acceleration, progressive and nonprogressive CPP, and early puberty. Measurement of basal and stimulated LH levels remains challenging, considering that the levels are not always in the pubertal range at baseline, short-acting GnRH is not readily available in Brazil, and the cutoff values differ according to the laboratory assay. When CPP is suspected but basal LH values are at prepubertal range, a stimulation test with short-acting or long-acting monthly GnRH is a diagnostic option. In Brazil, the treatment of choice for progressive CPP and early puberty is a long-acting GnRH analog (GnRHa) administered once a month or every 3 months. In Brazil, formulations of GnRHa (leuprorelin and triptorelin) are available and commonly administered, including 1-month depot leuprorelin 3.75 mg and 7.5 mg, 1-month depot triptorelin 3.75 mg, and 3-month depot leuprorelin 11.25 mg. Monthly or 3-month depot GnRHa are effective and safe to treat CPP. Arch Endocrinol Metab. 2016;60(2):163-72 |
| abstract_unstemmed |
ABSTRACT Clinical and laboratory diagnosis and treatment of central precocious puberty (CPP) remain challenging due to lack of standardization. The aim of this revision was to address the diagnostic and therapeutic features of CPP in Brazil based on relevant international literature and availability of the existing therapies in the country. The diagnosis of CPP is based mainly on clinical and biochemical parameters, and a period of follow-up is desirable to define the “progressive” form of sexual precocity. This occurs due to the broad spectrum of pubertal development, including isolated premature thelarche, constitutional growth and puberty acceleration, progressive and nonprogressive CPP, and early puberty. Measurement of basal and stimulated LH levels remains challenging, considering that the levels are not always in the pubertal range at baseline, short-acting GnRH is not readily available in Brazil, and the cutoff values differ according to the laboratory assay. When CPP is suspected but basal LH values are at prepubertal range, a stimulation test with short-acting or long-acting monthly GnRH is a diagnostic option. In Brazil, the treatment of choice for progressive CPP and early puberty is a long-acting GnRH analog (GnRHa) administered once a month or every 3 months. In Brazil, formulations of GnRHa (leuprorelin and triptorelin) are available and commonly administered, including 1-month depot leuprorelin 3.75 mg and 7.5 mg, 1-month depot triptorelin 3.75 mg, and 3-month depot leuprorelin 11.25 mg. Monthly or 3-month depot GnRHa are effective and safe to treat CPP. Arch Endocrinol Metab. 2016;60(2):163-72 |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ |
| title_short |
Central precocious puberty: revisiting the diagnosis and therapeutic management |
| url |
https://doi.org/10.1590/2359-3997000000144 https://doaj.org/article/a389ff385f434983afbf79f948d87294 http://www.scielo.br/scielo.php?script=sci_arttext&pid=S2359-39972016000200163&lng=en&tlng=en https://doaj.org/toc/2359-4292 |
| remote_bool |
true |
| author2 |
Angela Maria Spinola-Castro Cristiane Kochi Cristiane Kopacek Paulo César Alves da Silva Gil Guerra-Júnior |
| author2Str |
Angela Maria Spinola-Castro Cristiane Kochi Cristiane Kopacek Paulo César Alves da Silva Gil Guerra-Júnior |
| ppnlink |
1760589977 |
| callnumber-subject |
RC - Internal Medicine |
| mediatype_str_mv |
c |
| isOA_txt |
true |
| hochschulschrift_bool |
false |
| doi_str |
10.1590/2359-3997000000144 |
| callnumber-a |
RC648-665 |
| up_date |
2024-07-03T23:49:26.233Z |
| _version_ |
1803603742540431360 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ056983166</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230308205216.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230227nuuuuuuuuxx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1590/2359-3997000000144</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ056983166</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJa389ff385f434983afbf79f948d87294</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC648-665</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Vinícius Nahime Brito</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Central precocious puberty: revisiting the diagnosis and therapeutic management</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">ABSTRACT Clinical and laboratory diagnosis and treatment of central precocious puberty (CPP) remain challenging due to lack of standardization. The aim of this revision was to address the diagnostic and therapeutic features of CPP in Brazil based on relevant international literature and availability of the existing therapies in the country. The diagnosis of CPP is based mainly on clinical and biochemical parameters, and a period of follow-up is desirable to define the “progressive” form of sexual precocity. This occurs due to the broad spectrum of pubertal development, including isolated premature thelarche, constitutional growth and puberty acceleration, progressive and nonprogressive CPP, and early puberty. Measurement of basal and stimulated LH levels remains challenging, considering that the levels are not always in the pubertal range at baseline, short-acting GnRH is not readily available in Brazil, and the cutoff values differ according to the laboratory assay. When CPP is suspected but basal LH values are at prepubertal range, a stimulation test with short-acting or long-acting monthly GnRH is a diagnostic option. In Brazil, the treatment of choice for progressive CPP and early puberty is a long-acting GnRH analog (GnRHa) administered once a month or every 3 months. In Brazil, formulations of GnRHa (leuprorelin and triptorelin) are available and commonly administered, including 1-month depot leuprorelin 3.75 mg and 7.5 mg, 1-month depot triptorelin 3.75 mg, and 3-month depot leuprorelin 11.25 mg. Monthly or 3-month depot GnRHa are effective and safe to treat CPP. Arch Endocrinol Metab. 2016;60(2):163-72</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Precocious puberty</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">sexual maturation</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">gonadotropin-realising hormone</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">luteinizing hormone</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">long-acting GnRH analog</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medicine</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">R</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Diseases of the endocrine glands. Clinical endocrinology</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Angela Maria Spinola-Castro</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Cristiane Kochi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Cristiane Kopacek</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Paulo César Alves da Silva</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Gil Guerra-Júnior</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Archives of Endocrinology and Metabolism</subfield><subfield code="d">Brazilian Society of Endocrinology and Metabolism, 2017</subfield><subfield code="w">(DE-627)1760589977</subfield><subfield code="x">23594292</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1590/2359-3997000000144</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/a389ff385f434983afbf79f948d87294</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://www.scielo.br/scielo.php?script=sci_arttext&pid=S2359-39972016000200163&lng=en&tlng=en</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2359-4292</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield></record></collection>
|
| score |
7.3986006 |